Best Stocks Under $2 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. Senseonics NYSE:SENS$0.42 -0.03 (-6.25%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. More about SenseonicsMarket Capitalization$342.98 millionP/E Ratio-3.24Consensus RatingBuyConsensus Price Target$1.54 (+266.1% Upside)Volume9.01 million sharesAverage Volume8.17 million shares Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. Ur Energy NYSEAMERICAN:URG$1.94 +0.03 (+1.31%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur EnergyMarket Capitalization$706.92 millionP/E Ratio-11.32Consensus RatingBuyConsensus Price Target$2.44 (+26.1% Upside)Volume15.10 million sharesAverage Volume6.00 million shares3. Marker Therapeutics NASDAQ:MRKR$1.01 -0.04 (-3.81%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. More about Marker TherapeuticsMarket Capitalization$13.07 millionP/E Ratio-0.74Consensus RatingBuyConsensus Price Target$13.17 (+1,203.6% Upside)Volume232,185 sharesAverage Volume750,382 shares4. Quince Therapeutics NASDAQ:QNCX$1.88 -0.17 (-8.09%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince TherapeuticsMarket Capitalization$100.38 millionP/E Ratio-1.71Consensus RatingBuyConsensus Price Target$8.14 (+334.3% Upside)Volume410,235 sharesAverage Volume247,702 shares5. Cardiol Therapeutics NASDAQ:CRDL$1.04 -0.05 (-4.13%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about Cardiol TherapeuticsMarket Capitalization$89.81 millionP/E Ratio-3.07Consensus RatingBuyConsensus Price Target$8.00 (+665.6% Upside)Volume525,369 sharesAverage Volume445,577 shares6. Talphera NASDAQ:TLPH$1.22 -0.05 (-3.94%) As of 03:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. More about TalpheraMarket Capitalization$55.62 millionP/E Ratio-3.05Consensus RatingBuyConsensus Price Target$5.00 (+309.8% Upside)Volume315,829 sharesAverage Volume930,837 shares7. Climb Bio NASDAQ:CLYM$1.80 -0.09 (-4.76%) As of 03:22 PM EasternClimb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. More about Climb BioMarket Capitalization$121.98 millionP/E Ratio-2.57Consensus RatingBuyConsensus Price Target$9.25 (+413.9% Upside)Volume408,326 sharesAverage Volume383,054 shares8. Aclaris Therapeutics NASDAQ:ACRS$1.88 -0.08 (-3.85%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris TherapeuticsMarket Capitalization$203.12 millionP/E Ratio-1.37Consensus RatingModerate BuyConsensus Price Target$8.71 (+364.8% Upside)Volume419,277 sharesAverage Volume968,254 shares9. Context Therapeutics NASDAQ:CNTX$1.36 -0.04 (-2.86%) As of 03:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context TherapeuticsMarket Capitalization$121.99 millionP/E Ratio-3.78Consensus RatingModerate BuyConsensus Price Target$5.20 (+282.4% Upside)Volume900,540 sharesAverage Volume208,305 shares10. Ovid Therapeutics NASDAQ:OVID$1.66 -0.08 (-4.31%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid TherapeuticsMarket Capitalization$118.40 millionP/E Ratio-3.14Consensus RatingModerate BuyConsensus Price Target$3.70 (+122.2% Upside)Volume3.47 million sharesAverage Volume1.49 million shares11. zSpace NASDAQ:ZSPC$1.27 -0.20 (-13.91%) As of 03:27 PM EasternzSpace Technologies, Inc is a provider of commercial augmented reality and virtual reality technology principally in the education market. More about zSpaceMarket Capitalization$30.42 millionConsensus RatingModerate BuyConsensus Price Target$10.00 (+690.2% Upside)Volume1.73 million sharesAverage Volume349,254 sharesToday's Range$1.25▼$1.5312. Invivyd NASDAQ:IVVD$1.76 -0.13 (-6.61%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. More about InvivydMarket Capitalization$212.05 millionP/E Ratio-1.92Consensus RatingModerate BuyConsensus Price Target$5.14 (+191.1% Upside)Volume7.05 million sharesAverage Volume7.64 million shares13. Mereo BioPharma Group NASDAQ:MREO$1.96 -0.14 (-6.43%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. More about Mereo BioPharma GroupMarket Capitalization$312.44 millionP/E Ratio-28.07Consensus RatingModerate BuyConsensus Price Target$7.40 (+276.6% Upside)Volume913,812 sharesAverage Volume1.64 million shares14. i-80 Gold NYSE:IAUX$0.93 -0.03 (-2.83%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.i-80 Gold Corp. is a mining company, engages in the exploration, development and production of gold and silver mineral deposits principally in the United States. More about i-80 GoldMarket Capitalization$734.52 millionP/E Ratio-2.58Consensus RatingModerate BuyConsensus Price Target$1.50 (+61.6% Upside)Volume5.67 million sharesAverage Volume5.99 million shares15. Plus Therapeutics NASDAQ:PSTV$0.70 -0.03 (-3.68%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. More about Plus TherapeuticsMarket Capitalization$69.19 millionP/E Ratio-0.31Consensus RatingModerate BuyConsensus Price Target$8.00 (+1,049.4% Upside)Volume13.31 million sharesAverage Volume21.07 million shares16. PowerBank NASDAQ:SUUN$1.97 -0.08 (-4.00%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SolarBank Corporation operates as an independent renewable and clean energy project developer and asset operator in Canada and the United States. More about PowerBankMarket Capitalization$72.11 millionP/E Ratio-12.30Consensus RatingModerate BuyConsensus Price Target$5.00 (+154.1% Upside)Volume297,311 sharesAverage Volume295,951 shares17. Cognition Therapeutics NASDAQ:CGTX$1.82 -0.14 (-6.92%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. More about Cognition TherapeuticsMarket Capitalization$133.44 millionP/E Ratio-2.71Consensus RatingModerate BuyConsensus Price Target$2.83 (+56.1% Upside)Volume2.12 million sharesAverage Volume4.71 million shares18. Reviva Pharmaceuticals NASDAQ:RVPH$0.63 -0.15 (-19.24%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva PharmaceuticalsMarket Capitalization$43.41 millionP/E Ratio-0.96Consensus RatingModerate BuyConsensus Price Target$4.86 (+666.1% Upside)Volume17.41 million sharesAverage Volume3.42 million shares19. Biomea Fusion NASDAQ:BMEA$1.66 -0.13 (-6.98%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. More about Biomea FusionMarket Capitalization$99.08 millionP/E Ratio-0.55Consensus RatingModerate BuyConsensus Price Target$9.50 (+470.6% Upside)Volume2.76 million sharesAverage Volume1.47 million shares20. Gain Therapeutics NASDAQ:GANX$1.94 -0.15 (-6.97%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. More about Gain TherapeuticsMarket Capitalization$69.92 millionP/E Ratio-3.09Consensus RatingModerate BuyConsensus Price Target$7.86 (+306.1% Upside)Volume888,932 sharesAverage Volume362,863 shares21. Acrivon Therapeutics NASDAQ:ACRV$1.88 -0.08 (-4.13%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. More about Acrivon TherapeuticsMarket Capitalization$59.11 millionP/E Ratio-0.84Consensus RatingModerate BuyConsensus Price Target$15.00 (+698.3% Upside)Volume576,467 sharesAverage Volume737,803 shares22. Autolus Therapeutics NASDAQ:AUTL$1.64 -0.13 (-7.10%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More about Autolus TherapeuticsMarket Capitalization$432.48 millionP/E Ratio-1.93Consensus RatingModerate BuyConsensus Price Target$9.12 (+457.8% Upside)Volume2.07 million sharesAverage Volume2.36 million shares23. Lucid Diagnostics NASDAQ:LUCD$1.16 -0.07 (-5.28%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid DiagnosticsMarket Capitalization$155.50 millionP/E Ratio-0.98Consensus RatingModerate BuyConsensus Price Target$3.70 (+217.6% Upside)Volume1.58 million sharesAverage Volume1.09 million shares24. Werewolf Therapeutics NASDAQ:HOWL$1.64 -0.14 (-7.87%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. More about Werewolf TherapeuticsMarket Capitalization$75.45 millionP/E Ratio-1.01Consensus RatingModerate BuyConsensus Price Target$8.00 (+387.8% Upside)Volume1.16 million sharesAverage Volume469,369 shares25. InflaRx NASDAQ:IFRX$1.38 -0.08 (-5.14%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. More about InflaRxMarket Capitalization$92.98 millionP/E Ratio-1.73Consensus RatingModerate BuyConsensus Price Target$6.20 (+347.7% Upside)Volume488,543 sharesAverage Volume465,269 shares More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
